Neuroleptic malignant syndrome (NMS) is one of the most dangerous complications of Neuroleptic therapy, often resulting in fatal patients with schizophrenia.
CSN usually develops on the 2-3 week beginning neuroleptic therapy and most frequently when applying powerful doses with marked General and electoral antipsihoticheskim activity and high ekstrapiramidna activity, such as tioprolerazin (mazheptil), haloperidol, trifluoperazine (trifluoperazine) and etc.
Neirolepticeski malignant syndrome can occur at any age, but is most commonly seen in young men. CSN is described in patients with various psychiatric diagnoses (schizophrenia, affective psychoses, delirium tremens, neurosis, mental retardation). Risk factors are interkurrentnaja CSN infection, physical exhaustion, violations of water-electrolyte balance (primarily dehydration or hyponatremia), thyroid dysfunction, organic disease of CENTRAL NERVOUS SYSTEM. Describes cases of CSN after canceling holinolitikov, However, they did not warn the CSN.
The first symptoms of malignant neuroleptic syndrome is characterized by the emergence of extrapyramidal symptoms as akineto dosage or dosage giperkineto syndromes with simultaneous exacerbation of psychotic on jekstrapiramidno-psihoticheskomu type with a predominance of katatonicheskih disorders (stupor with catalepsy or negativity). When weighting the status, increasing somatic violations, усилении гипертермии происходит смена эндогенных – онейроидно-кататонических расстройств экзогенными – аментивными и сопорозно-коматозными.
In the overall analysis of blood marked characteristic changes, that along with the clinical symptoms can be used to diagnose. Characteristic is the increase in ESR before 15-70 mm / h, percentage reduction in the number of lymphocytes to 3-17 with a slight Leukocytosis, reduction of serum protein prior to 45-65 g / l, increased levels of urea to 5,8-12,3 mmol/l and creatinine to 0,15 mmol / l.
CSN is more often described in schizophrenia and affective psychosis, but can occur and in patients with other diseases (dementia, delirium tremens, oligofrenia, Parkinson's disease, Huntington's chorea, Wilson's disease, striatonigralnoj degeneration, When other neurological pathology), as well as in healthy individuals when assigning them antipsychotics or other dopaminugnetajushhih drugs, or when receiving dopamine agonists is interrupted.
Treatment consists in withdrawal, caused neirolepticeski syndrome, If you cannot cancel the selection of substitution treatment or reducing the dose. Appointed by benzodiazepines, amantadin, antispasmodics, vitamins, anticonvulsants, correction is carried out of existing violations of breath, hemodynamics, acid-base balance.
NMS, usually, evolving from the first symptoms to peak within 1-2-3 Nights. Sometimes there is a lightning-fast development, from first signs up to the height of passes just a few hours. Lightning-quick form especially fatal.
If mental disorders, over which a nejrolepticheskaja therapy, require its resumption after suffering an episode of CSN, repeated treatment antipsihotikami should be carried out only with the full disappearance of all the symptoms of complications.
Resumption of therapy should take place under strict clinical supervision to prevent recurrence of malignant neuroleptic syndrome.
This site uses cookies and services to collect technical data from visitors to ensure performance and improve the quality of service.. By continuing to use our site, you automatically agree to the use of these technologies.
Read More